Coldstream Capital Management Inc. Has $746,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

Coldstream Capital Management Inc. grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 10.0% in the 4th quarter, HoldingsChannel reports. The fund owned 10,354 shares of the medical equipment provider’s stock after purchasing an additional 944 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Hologic were worth $746,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of HOLX. Barclays PLC lifted its position in Hologic by 47.6% during the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after acquiring an additional 231,578 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Hologic in the third quarter valued at approximately $93,000. Tidal Investments LLC grew its position in Hologic by 60.1% during the third quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider’s stock worth $1,250,000 after buying an additional 5,764 shares in the last quarter. Franklin Resources Inc. increased its stake in Hologic by 171.7% during the 3rd quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider’s stock worth $22,714,000 after acquiring an additional 175,855 shares during the period. Finally, Oddo BHF Asset Management Sas acquired a new position in Hologic in the 3rd quarter valued at $1,110,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of HOLX stock opened at $58.08 on Tuesday. The business’s 50-day moving average price is $60.90 and its 200-day moving average price is $69.77. Hologic, Inc. has a 12 month low of $55.89 and a 12 month high of $84.67. The firm has a market capitalization of $13.03 billion, a price-to-earnings ratio of 18.32, a PEG ratio of 2.14 and a beta of 0.82. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Morgan Stanley reduced their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a report on Monday, February 3rd. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Argus lowered Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Evercore ISI reduced their target price on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Hologic presently has an average rating of “Hold” and a consensus target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.